{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:30:57Z","timestamp":1772753457809,"version":"3.50.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bbcan.2025.189288","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T23:16:56Z","timestamp":1740266216000},"page":"189288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overview of splicing variation in ovarian cancer"],"prefix":"10.1016","volume":"1880","author":[{"given":"Min","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoer","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","article-title":"Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2)","volume":"144","author":"Matz","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0025","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20212090","article-title":"Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment","volume":"42","author":"Sun","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bbcan.2025.189288_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.622182","article-title":"Immune modeling analysis reveals immunologic signatures associated with improved outcomes in high grade serous ovarian cancer","volume":"11","author":"James","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189288_bb0035","first-page":"1056431","article-title":"Integrative Network analysis reveals a MicroRNA-based signature for prognosis prediction of epithelial ovarian Cancer","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbcan.2025.189288_bb0040","article-title":"Identification of LncRNA prognostic markers for ovarian Cancer by integration of co-expression and CeRNA Network","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-021-02070-x","article-title":"PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models","volume":"40","author":"Morosi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-019-1245-5","article-title":"New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools","volume":"38","author":"Mu\u00f1oz-Galv\u00e1n","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yexcr.2018.03.014","article-title":"Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway","volume":"366","author":"Bai","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"5678","key":"10.1016\/j.bbcan.2025.189288_bb0060","article-title":"Evidence for splicing of interrupted immunoglobulin variable and constant region sequences in nuclear RNA","volume":"275","author":"Th","year":"1978","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189288_bb0065","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ng.259","article-title":"Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing","volume":"40","author":"Pan","year":"2008","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189288_bb0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrm.2017.27","article-title":"Alternative splicing as a regulator of development and tissue identity","volume":"18","author":"Baralle","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-021-01978-8","article-title":"Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1","volume":"40","author":"Du","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11684-016-0454-y","article-title":"Alternative splicing of inner-ear-expressed genes","volume":"10","author":"Wang","year":"2016","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0095","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1038\/s41598-021-89778-0","article-title":"Ouyang et al_2021_Alternative splicing acts as an independent prognosticator in ovarian carcinoma","volume":"11","author":"Yan","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189288_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2020.11.043","article-title":"Splicing factors: insights into their regulatory network in alternative splicing in cancer","volume":"501","author":"Du","year":"2021","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/nar\/gku1392","article-title":"Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer","volume":"43","author":"Sebesty\u00e9n","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"7418","key":"10.1016\/j.bbcan.2025.189288_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Network","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12885-023-10854-x","article-title":"Meta-analysis of Osteopontin splice variants in cancer","volume":"23","author":"An","year":"2023","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189288_bb0125","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","article-title":"The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal.Pdf","volume":"21","author":"Bingle","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189288_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cancergen.2021.05.007","article-title":"A hereditary ovarian cancer family with rare pathogenic splicing mutation: implications for variant interpretation","volume":"256\u2013257","author":"Wang","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189288_bb0135","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2025.189288_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/962038","article-title":"Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy","volume":"2013","author":"Bonomi","year":"2013","journal-title":"Int. J. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum. Mutat."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189288_bb0150","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/ejhg.2014.40","article-title":"Functional characterization of BRCA1 gene variants by mini-gene splicing assay","volume":"22","author":"Steffensen","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2025.189288_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2023.104856","article-title":"Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer","volume":"130","author":"Jasiak","year":"2023","journal-title":"Exp. Mol. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-024-02048-1","article-title":"BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance","volume":"23","author":"Nesic","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189288_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2021.06.003","article-title":"BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast\/ovarian cancer patients","volume":"258\u2013259","author":"Montalban","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"25","key":"10.1016\/j.bbcan.2025.189288_bb0170","doi-asserted-by":"crossref","first-page":"17334","DOI":"10.18632\/oncotarget.24671","article-title":"Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and\/or ovarian cancer","volume":"9","author":"Caputo","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189288_bb0175","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/humu.24276","article-title":"Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants","volume":"42","author":"Ruiz de Garibay","year":"2021","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0180","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/genes13040697","article-title":"Case review: whole-exome sequencing analyses identify carriers of a known likely pathogenic Intronic BRCA1 variant in ovarian Cancer cases clinically negative for pathogenic BRCA1 and BRCA2 variants","volume":"13","author":"Alenezi","year":"2022","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189288_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2019.07.005","article-title":"Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma","volume":"461","author":"Yu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189288_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154896","article-title":"Citri Reticulatae Pericarpium-Reynoutria japonica Houtt. Herb pair suppresses breast cancer liver metastasis by targeting ECM1-mediated cholesterol biosynthesis pathway","volume":"116","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0945-053X(97)90017-2","article-title":"Characterization of the human extracellular matrix protein 1 gene on chromosome 1q21","volume":"16","author":"Johnson","year":"1997","journal-title":"Matrix Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0205","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1006\/geno.1997.4918","article-title":"The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization","volume":"45","author":"Smits","year":"1997","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0210","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1038\/s41467-021-24315-1","article-title":"Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness","volume":"12","author":"Yin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189288_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18632\/oncoscience.575","article-title":"UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?","volume":"10","author":"Husein","year":"2023","journal-title":"Oncoscience"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-022-01317-0","article-title":"The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer","volume":"15","author":"Inigo","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"34","key":"10.1016\/j.bbcan.2025.189288_bb0225","doi-asserted-by":"crossref","first-page":"12741","DOI":"10.1073\/pnas.0605457103","article-title":"Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids","volume":"103","author":"Gargalovic","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/mp.51.4.191","article-title":"The normal structure and function of CD44 and its role in neoplasia","volume":"51","author":"Sneath","year":"1998","journal-title":"Mol. Pathol."},{"issue":"5B","key":"10.1016\/j.bbcan.2025.189288_bb0235","first-page":"3901","article-title":"Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases","volume":"19","author":"Schr\u00f6der","year":"1999","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189288_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156595","article-title":"CD44 splice variant v8-10 as a marker of serous ovarian Cancer prognosis","volume":"11","author":"Sosulski","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189288_bb0245","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/cas.12765","article-title":"CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer","volume":"106","author":"Tjhay","year":"2015","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0250","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1002\/jcb.26504","article-title":"Mesenchymal splice isoform of CD44 (CD44s) promotes EMT\/invasion and imparts stem-like properties to ovarian cancer cells","volume":"119","author":"Bhattacharya","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189288_bb0255","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1101\/gad.1430906","article-title":"A positive feedback loop couples Ras activation and CD44 alternative splicing","volume":"20","author":"Cheng","year":"2006","journal-title":"Genes Dev."},{"issue":"Pt 5","key":"10.1016\/j.bbcan.2025.189288_bb0260","article-title":"Role of TI-VAMP and CD82 in EGFR cell-surface dynamics and signaling","volume":"123","author":"Danglot","year":"2010","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0265","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cellsig.2014.11.028","article-title":"Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin \u03b1v\u03b23-mediated ovarian cancer biology","volume":"27","author":"Upheber","year":"2015","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0270","article-title":"Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review)","volume":"13","author":"Reuning","year":"1998","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189288_bb0275","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.yexcr.2009.01.007","article-title":"Tumor suppressor KAI1 affects integrin \u03b1v\u03b23-mediated ovarian cancer cell adhesion, motility, and proliferation","volume":"315","author":"Ruseva","year":"2009","journal-title":"Exp. Cell Res."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189288_bb0280","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1073\/pnas.91.19.8822","article-title":"The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump","volume":"91","author":"Zaman","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0285","first-page":"357","article-title":"Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs","volume":"54","author":"Grant","year":"1994","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189288_bb0290","first-page":"5902","article-title":"Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells","volume":"54","author":"Cole","year":"1994","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189288_bb0295","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-03-0439","article-title":"Alternative splicing of the multidrug resistance protein 1\/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20","volume":"10","author":"He","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0300","first-page":"773","article-title":"Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair","volume":"6","author":"Yang","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.bbcan.2025.189288_bb0305","doi-asserted-by":"crossref","first-page":"23419","DOI":"10.1074\/jbc.273.36.23419","article-title":"Cisplatin induction of ERCC-1 mRNA expression in A2780\/CP70 human ovarian cancer cells","volume":"273","author":"Li","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189288_bb0310","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.4161\/cc.26309","article-title":"ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform","volume":"12","author":"Friboulet","year":"2013","journal-title":"Cell Cycle"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189288_bb0315","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/nar\/24.17.3370","article-title":"Mutational analysis of the human nucleotide excision repair gene ERCC1","volume":"24","author":"Sijbers","year":"1996","journal-title":"Nucleic Acids Res."},{"issue":"52","key":"10.1016\/j.bbcan.2025.189288_bb0320","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1038\/sj.onc.1204977","article-title":"An ERCC1 splicing variant involving the 5\u2019-UTR of the mRNA may have a transcriptional modulatory function","volume":"20","author":"Yu","year":"2001","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189288_bb0325","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/07357900902744536","article-title":"The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells","volume":"27","author":"Sun","year":"2009","journal-title":"Cancer Investig."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189288_bb0330","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/ijms19092557","article-title":"The phylogeny of Osteopontin\u2014analysis of the protein sequence","volume":"19","author":"Weber","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2017.02.005","article-title":"Osteopontin splice variants and polymorphisms in cancer progression and prognosis","volume":"1868","author":"Briones-Orta","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0340","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2004.01.050","article-title":"Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer","volume":"93","author":"Brakora","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189288_bb0345","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00432-010-0968-7","article-title":"Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer","volume":"137","author":"Zhao","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189288_bb0350","first-page":"1707","article-title":"Osteopontin b and c isoforms: molecular candidates associated with leukemic stem cell Chemoresistance in acute myeloid leukemia","volume":"18","author":"Mirzaei","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189288_bb0355","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/neuonc\/noq006","article-title":"Expression pattern of osteopontin splice variants and its functions on cell.Pdf","volume":"12","author":"Yan","year":"2010","journal-title":"Neuro-Oncology"},{"issue":"6\u20137","key":"10.1016\/j.bbcan.2025.189288_bb0360","article-title":"Assessing SPP1\/Osteopontin (OPN) splice variants and their association to nonmelanoma skin Cancer by absolute quantification: identification of OPN-5 subvariants and their protein coding potential","volume":"39","author":"Cf","year":"2021","journal-title":"Cancer Investig."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0365","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2015.01.002","article-title":"Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth","volume":"57","author":"Kashatus","year":"2015","journal-title":"Mol. Cell"},{"issue":"37","key":"10.1016\/j.bbcan.2025.189288_bb0370","doi-asserted-by":"crossref","first-page":"60021","DOI":"10.18632\/oncotarget.11047","article-title":"Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients","volume":"7","author":"Tanwar","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0375","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tibs.2016.02.001","article-title":"Making a division apparatus on mitochondria","volume":"41","author":"Yamada","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0380","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1074\/jbc.M115.680181","article-title":"Distinct splice variants of dynamin-related protein 1 differentially utilize mitochondrial fission factor as an effector of cooperative GTPase activity","volume":"291","author":"Macdonald","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189288_bb0385","article-title":"New perspectives on the role of Drp1 isoforms in regulating mitochondrial pathophysiology","volume":"213","author":"Aa","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189288_bb0390","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/s44319-024-00232-4","article-title":"Drp1 splice variants regulate ovarian cancer mitochondrial dynamics and tumor progression","volume":"25","author":"Javed","year":"2024","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0395","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41598-021-03836-1","article-title":"Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment","volume":"12","author":"Yue","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189288_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678400","article-title":"Significance of PD1 alternative splicing in celiac disease as a novel source for diagnostic and therapeutic target","volume":"12","author":"Ponce de Le\u00f3n","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189288_bb0405","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0410","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","article-title":"A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression","volume":"68","author":"Mahoney","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0415","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/cimm.2000.1649","article-title":"A native soluble form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0420","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189288_bb0425","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00018-022-04359-2","article-title":"The HLA-G immune checkpoint: a new immuno-stimulatory role for the \u03b11-domain-deleted isoform","volume":"79","author":"Tronik-Le Roux","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2025.189288_bb0430","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2013.06.004","article-title":"The splicing factor hnRNP C regulates expression of co-stimulatory molecules CD80 and CD40 in dendritic cells","volume":"153","author":"Jia","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbcan.2025.189288_bb0435","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/462658","article-title":"Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer","volume":"2014","author":"Valente","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0440","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.7314\/APJCP.2014.15.5.2153","article-title":"Alternative messenger RNA splicing of autophagic gene Beclin 1 in human B-cell acute lymphoblastic leukemia cells","volume":"15","author":"Niu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0445","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/s41467-022-30433-1","article-title":"Autophagy regulation by RNA alternative splicing and implications in human diseases","volume":"13","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189288_bb0450","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/biom12081069","article-title":"Isolation, characterization, and autophagy function of BECN1-splicing isoforms in Cancer cells","volume":"12","author":"Maheshwari","year":"2022","journal-title":"Biomolecules"},{"issue":"20","key":"10.1016\/j.bbcan.2025.189288_bb0455","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1111\/jcmm.17540","article-title":"SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP","volume":"26","author":"Chen","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0460","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbrc.2017.02.094","article-title":"SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5","volume":"485","author":"Cai","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2025.189288_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2017.11.003","article-title":"SNHG16\/miR-216-5p\/ZEB1 signal pathway contributes to the tumorigenesis of cervical cancer cells","volume":"637","author":"Zhu","year":"2018","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0470","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.18632\/oncotarget.23178","article-title":"SNHG16\/miR-140-5p axis promotes esophagus cancer cell proliferation, migration and EMT formation through regulating ZEB1","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0475","doi-asserted-by":"crossref","first-page":"275","DOI":"10.32604\/or.2022.03561","article-title":"PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16\/CEBPB\/GATA3 axis","volume":"29","author":"Wang","year":"2021","journal-title":"Oncol. Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189288_bb0480","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1101\/gr.202895.115","article-title":"Diverse alternative back-splicing and alternative splicing landscape of circular RNAs","volume":"26","author":"Zhang","year":"2016","journal-title":"Genome Res."},{"key":"10.1016\/j.bbcan.2025.189288_bb0485","doi-asserted-by":"crossref","unstructured":"Zhao Z, Ji M, Wang Q, He N, Li Y. Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression. Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33. doi: 10.1016\/j.omtn.2019.07.012IF: 6.5 Q1. Epub 2019 Jul 29. Retraction in: Mol Ther Nucleic Acids. 2024 May 19;35(2):102213. doi: 10.1016\/j.omtn.2024.102213. PMID: 31479922; PMCID: PMC6726918.","DOI":"10.1016\/j.omtn.2024.102213"},{"key":"10.1016\/j.bbcan.2025.189288_bb0490","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.omtn.2019.12.005","article-title":"circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0495","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","article-title":"Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed","volume":"58","author":"Rybak-Wolf","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2025.189288_bb0500","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.2147\/OTT.S220700","article-title":"Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bbcan.2025.189288_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.574338","article-title":"The multifaceted roles of the BCL-2 family member BOK","volume":"8","author":"Naim","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2025.189288_bb0510","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.omtn.2023.07.034","article-title":"Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme","volume":"33","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189288_bb0515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13048-020-00685-w","article-title":"circRNA-UBAP2 promotes the proliferation and inhibits apoptosis of ovarian cancer though miR-382-5p\/PRPF8 axis","volume":"13","author":"Xu","year":"2020","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0520","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41420-020-00381-0","article-title":"Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression","volume":"7","author":"Chen","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-020-01163-z","article-title":"CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a","volume":"19","author":"Gan","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7280","key":"10.1016\/j.bbcan.2025.189288_bb0530","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature08909","article-title":"Expansion of the eukaryotic proteome by alternative splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"issue":"7569","key":"10.1016\/j.bbcan.2025.189288_bb0535","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"Hsu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189288_bb0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-015-0234-3","article-title":"The spliceosome, a potential Achilles heel of MYC-driven tumors","volume":"7","author":"Anczuk\u00f3w","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.bbcan.2025.189288_bb0545","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39030","article-title":"Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12\/13","volume":"7","author":"Zeng","year":"2018","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0550","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bbrc.2004.05.228","article-title":"Characterization of the BUD31 gene of Saccharomyces cerevisiae","volume":"320","author":"Masciadri","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0555","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1038\/s41467-022-34042-w","article-title":"Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189288_bb0560","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41419-021-03581-3","article-title":"Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189288_bb0565","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-29073-7_9","article-title":"Splicing factor mutations in Cancer","volume":"907","author":"Bejar","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0570","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1261\/rna.042838.113","article-title":"The crystal structure of S. Cerevisiae Sad1, a catalytically inactive deubiquitinase that is broadly required for pre-mRNA splicing","volume":"20","author":"Hadjivassiliou","year":"2014","journal-title":"RNA"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189288_bb0575","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1535-7163.MCT-09-0051","article-title":"Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells","volume":"8","author":"Albert","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189288_bb0580","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00109-013-1028-y","article-title":"MALAT1 -- a paradigm for long noncoding RNA function in cancer","volume":"91","author":"Gutschner","year":"2013","journal-title":"J. Mol. Med. (Berl)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0585","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/0008-5472.CAN-12-2850","article-title":"The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells","volume":"73","author":"Gutschner","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189288_bb0590","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","article-title":"The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation","volume":"39","author":"Tripathi","year":"2010","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155250","article-title":"The long noncoding RNA MALAT-1 is highly expressed in ovarian Cancer and induces cell growth and migration","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0600","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mc.22919","article-title":"The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing","volume":"58","author":"Gordon","year":"2019","journal-title":"Mol. Carcinog."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189288_bb0605","first-page":"850","article-title":"Overexpression of epithelial splicing regulatory protein 1 in metastatic lesions of serous ovarian carcinoma correlates with poor patient prognosis","volume":"37","author":"Lu","year":"2022","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bbcan.2025.189288_bb0610","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12935-020-01254-3","article-title":"High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer","volume":"20","author":"Deng","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0615","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.devcel.2019.03.017","article-title":"The alternative splicing regulator Nova2 constrains vascular Erk signaling to limit specification of the lymphatic lineage","volume":"49","author":"Baek","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbcan.2025.189288_bb0620","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44305","article-title":"A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing","volume":"8","author":"Angiolini","year":"2019","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0625","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41388-022-02539-9","article-title":"TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing","volume":"42","author":"He","year":"2023","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189288_bb0630","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1038\/s41388-020-1292-6","article-title":"Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity","volume":"39","author":"Pellarin","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2019.100750","article-title":"PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA double-Strand break repair genes","volume":"23","author":"Owens","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2025.189288_bb0640","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fgene.2013.00037","article-title":"The ATM signaling network in development and disease","volume":"4","author":"Stracker","year":"2013","journal-title":"Front. Genet."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189288_bb0645","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/2767-9764.CRC-23-0070","article-title":"PRMT5 inhibitors regulate DNA damage repair pathways in Cancer cells and improve response to PARP inhibition and chemotherapies","volume":"3","author":"Carter","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189288_bb0650","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.3892\/ol.2015.3137","article-title":"Hybrid-polymerase chain reaction to identify novel target genes of miR-134 in paclitaxel resistant human ovarian carcinoma cells","volume":"9","author":"Shuang","year":"2015","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189288_bb0655","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ajhg.2011.04.008","article-title":"A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa","volume":"88","author":"Tanackovic","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2025.189288_bb0660","doi-asserted-by":"crossref","first-page":"1009430","DOI":"10.3389\/fgene.2022.1009430","article-title":"Microtubule modification defects underlie cilium degeneration in cell models of retinitis pigmentosa associated with pre-mRNA splicing factor mutations","volume":"13","author":"Nazlamova","year":"2022","journal-title":"Front. Genet."},{"issue":"31","key":"10.1016\/j.bbcan.2025.189288_bb0665","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1038\/s41388-023-02763-x","article-title":"The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2","volume":"42","author":"Li","year":"2023","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189288_bb0670","first-page":"179","article-title":"The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts, \u201cSF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52,\u201d","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189288_bb0675","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1084\/jem.20081211","article-title":"The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells","volume":"206","author":"Maddaluno","year":"2009","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189288_bb0680","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1172\/JCI70683","article-title":"Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization","volume":"124","author":"Magrini","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189288_bb0685","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189288_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-2823-2_1","article-title":"miRNA biogenesis and regulation of diseases: An updated overview","volume":"2595","author":"Vishnoi","year":"2023","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189288_bb0695","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3390\/biomedicines9121818","article-title":"MicroRNA and alternative mRNA splicing events in Cancer drug response\/resistance: potent therapeutic targets","volume":"9","author":"Marima","year":"2021","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189288_bb0700","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41419-023-06301-1","article-title":"Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with \u03b1PDL1 in ovarian cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7571","key":"10.1016\/j.bbcan.2025.189288_bb0705","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature15394","article-title":"An integrated map of structural variation in 2,504 human genomes","volume":"526","author":"Sudmant","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189288_bb0710","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s41467-017-01343-4","article-title":"Mapping and phasing of structural variation in patient genomes using nanopore sequencing","volume":"8","author":"Cretu Stancu","year":"2017","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189288_bb0715","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky411","article-title":"Selective nanopore sequencing of human BRCA1 by Cas9-assisted targeting of chromosome segments (CATCH)","volume":"46","author":"Gabrieli","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189288_bb0720","article-title":"Hybrid-seq deciphers the complex transcriptional profile of the human BRCA1 DNA repair associated gene","volume":"20","author":"Pg","year":"2023","journal-title":"RNA Biol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:09:14Z","timestamp":1742296154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0304419X25000307"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189288","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of splicing variation in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189288"}}